This workshop will provide a practical introduction to positron emission tomography (PET) imaging. The basic physics and chemistry of PET will be presented, along with examples of its use in cancer, cardiovascular, and neurological research and patient management. The use of PET for diagnosis, staging, and treatment, in addition to monitoring of treatment will be discussed. Regulatory issues concerning the introduction of new PET imaging agents will be covered.
Our Fall Technologist Meeting is a one-day course designed especially for nuclear medicine technologists. We are only seeking VOICE credit (no other types of CEs). Attendees will gain up to seven VOICE credits for participating in this course.
NANETs/ SNMMI Symposium: Improvements in NET Imaging
Gallium-68-DOTA compounds that target somatostatin receptors have been used with PET to significantly improved the quality of imaging neuroendocrine tumors. Although approved in Europe, this class of agent has only been used in investigational trials under INDs in the US. Expanded efforts are underway to move them towards approval and into clinical practice. Recently, both 68Ga-DOTATOC and 68Ga-DOTATATE (GalioMedix ™) were granted orphan drug status by the FDA for the management of neuroendocrine tumors. These announcements have garnered widespread interest and elevated enthusiasm for using gallium imaging agents, but some issues related to using these agents remain unclear. Join David Dick, PhD, on Thursday, October 23 at 3:00pm ET, as he describes the current trials underway using the three Ga-68 DOTA agents (NOC/TATE/TOC) along with updates on the manufacturing, production and availability of the agents for clinical and/or investigational use.
Although the Centers for Medicare & Medicaid Services (CMS) denied coverage to Medicare beneficiaries for any clinical use of the technology, they left the door open for future approval pending more data on the benefits of amyloid imaging. In a process known as “coverage with evidence development” (CED), the agency will pay for a single scan for people participating in clinical trials designed to gather evidence about health outcomes. It would accept short-term outcomes such as a change in medication or avoidance of unnecessary tests as sufficient evidence of a health benefit. Join Maria Carrillo, PhD, as she presents the status of the community’s efforts during the year following CMS’s initial decision to collect additional data and provide an update by CMS on CED.
The ASN’s meeting each winter is a gathering of the major leaders in neurology who practice neuroimaging and of those who train and educate our medical students, residents and fellows. Participants include attending physicians, fellows and resident physicians, nurse practitioners and physician’s assistants who work predominantly in the field of neurology. We anticipate roughly 160 to attend; the ASN’s meeting environment is very intimate and allows for direct interaction with the meeting attendees. This year, our meeting program consist of clinically relevant neuroimaging including imaging of Parkinson’s disease, MS, Headache, Stroke, Epilepsy and more. The trainings are highly interactive and include image interpretation. The goal is to help those in attendance to understand the opportunities and strategies for incorporating imaging into clinical practice and to learn from and influence scientists who develop clinical solutions.
10th EMIM European Molecular Imaging Meeting
Organiser: ESMI European Society for Molecular Imaging Web: www.emim.eu
Date: 18-20 MARCH 2015
Venue: Kupferbau Tuebingen, Hölderlinstraße 5, 72074 Tübingen, Germany
Abstract categories: Cardiology Imaging Probes, Chemistry & Reporter Genes Imaging Technology, Methodology & Software Immunology/Inflammation Infectious Diseases Oncology Neurology Others
3rd November 2014| Opening of EMIM Abstract Submission
9th December 2014| DEADLINE for EMIM Abstract Submission
Our 60th Annual Meeting Program Co-chairs, Mike Clemenshaw, MD and Lucrecia Pantarotto, CNMT, in cooperation with the Program Committee, have begun developing educational sessions which will include a lot of Cardiac Nuclear Medicine as well as timely updates on General Nuclear Medicine Studies. At our 59th Annual Meeting, we offered nine SAM and we hope to match those numbers for 2015.
46th Annual Spring Educational Conference and Exhibition - MECSNM
Clinical Nuclear Medicine, PET-CT and PET-MRI is a well-established multidisciplinary post-graduate course designed for health care professionals involved in the practice of nuclear medicine and molecular imaging including nuclear medicine physicians, radiologists, fellows, residents, medical students, physicists and technologists. The objective of the course is to provide continuing and up-to-date professional development through the review of established clinical applications as well as new and emerging ones within the specialty of nuclear medicine and molecular imaging. Through a combination of lectures on various topics with a focus on CASE-BASED STUDIES with interactive audience participation using an electronic audience response system, the participants will be able to review a broad scope of new and advanced clinical applications, learn about technology innovations, and participate in Self-Assessment Modules (SAMs) to fulfill yearly Maintenance of Certification (MOC) requirement
The SNMMI Annual Meeting has been recognized by thousands of professional attendees as the premier educational and networking event in molecular imaging and nuclear medicine. The 2014 Annual Meeting will continue to build on past successes offering: the latest educational content; virtual learning opportunities both during the meeting and post-conference; networking events; and an exhibit hall packed with the latest technology.
Join David Schuster, MD, August 21 at 3 pm ET for a one-hour webinar and learn more about anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid (anti-[18F]FACBC)—a synthetic amino acid PET radiotracer that has shown promise in staging and restaging patients with prostate cancer—the current status of using FACBC, and results of key clinical trials.
SNMMI 2014 Patient Hill Day